RS20050047A - Indoline derivatives substituted in position 6,production and use thereof as medicaments - Google Patents

Indoline derivatives substituted in position 6,production and use thereof as medicaments

Info

Publication number
RS20050047A
RS20050047A YUP-2005/0047A YUP20050047A RS20050047A RS 20050047 A RS20050047 A RS 20050047A YU P20050047 A YUP20050047 A YU P20050047A RS 20050047 A RS20050047 A RS 20050047A
Authority
RS
Serbia
Prior art keywords
production
derivatives substituted
medicaments
indoline derivatives
salts
Prior art date
Application number
YUP-2005/0047A
Other languages
English (en)
Inventor
Gerald Jurgen Roth
Armin Heckel
Thorsten Lehmann-Lintz
Frank Hilberg
Grunt Ulrike Tontsch
Jacobus Van Meel
Original Assignee
Boehringer Ingelheim Pharma Gmbh.& Co.Kg.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10233366A external-priority patent/DE10233366A1/de
Priority claimed from DE10328533A external-priority patent/DE10328533A1/de
Application filed by Boehringer Ingelheim Pharma Gmbh.& Co.Kg., filed Critical Boehringer Ingelheim Pharma Gmbh.& Co.Kg.,
Publication of RS20050047A publication Critical patent/RS20050047A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na derivate indolinona, supstituisane u položaju 6, formule u kojoj R1 do R6 i X su kao što su definisani u Zahtevu 1, na njihove tautomere, enantiomere, dijastereomere, na njihove smeše i njihove soli, pre svega njihove fiziološki prihvatljive soli, koje poseduju korisne farmakološke karakteristike, posebno u inhibitornom dejstvu na različite receptorske tirozin kinaze i na proliferaciju endotelnih ćelija i različitih tumorskih ćelija, na lekove koji sadrže ova jedinjenja, na njihovu primenu i postupke za njihovo dobijanje.
YUP-2005/0047A 2002-07-23 2003-07-22 Indoline derivatives substituted in position 6,production and use thereof as medicaments RS20050047A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10233366A DE10233366A1 (de) 2002-07-23 2002-07-23 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10328533A DE10328533A1 (de) 2003-06-24 2003-06-24 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2003/007961 WO2004009547A1 (de) 2002-07-23 2003-07-22 In 6-stellung substituierte indolinonderivate, ihre herstellung und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
RS20050047A true RS20050047A (en) 2007-09-21

Family

ID=30771725

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0047A RS20050047A (en) 2002-07-23 2003-07-22 Indoline derivatives substituted in position 6,production and use thereof as medicaments

Country Status (25)

Country Link
EP (1) EP1523473B1 (sr)
JP (1) JP4401291B2 (sr)
KR (2) KR20050052456A (sr)
CN (1) CN1318403C (sr)
AR (1) AR041188A1 (sr)
AU (2) AU2003254557B2 (sr)
BR (1) BR0312799A (sr)
CA (1) CA2493436C (sr)
DK (1) DK1523473T3 (sr)
EA (1) EA008623B1 (sr)
EC (1) ECSP055567A (sr)
ES (1) ES2409062T3 (sr)
HK (1) HK1081554A1 (sr)
HR (1) HRP20050069A2 (sr)
IL (1) IL166404A0 (sr)
MX (1) MXPA04012937A (sr)
MY (1) MY138141A (sr)
NO (1) NO20050937L (sr)
PE (1) PE20040701A1 (sr)
PL (2) PL374879A1 (sr)
RS (1) RS20050047A (sr)
SA (1) SA03240430B1 (sr)
TW (1) TWI343375B (sr)
UY (1) UY27903A1 (sr)
WO (1) WO2004009547A1 (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20061155A1 (es) * 2004-12-24 2006-12-16 Boehringer Ingelheim Int Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
JP5053997B2 (ja) 2005-04-28 2012-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の治療用の新規化合物
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
RU2010135196A (ru) * 2008-01-25 2012-02-27 Бёрингер Ингельхайм Интернациональ Гмбх (De) Способ получения производного 6-фтор-1,2-дигидро-2-оксо-3н-индол-3-илидена
US20110130437A1 (en) * 2008-01-25 2011-06-02 Boehringer Ingelheim International Gmbh Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
JP5651110B2 (ja) 2008-07-29 2015-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
HUE034106T2 (en) * 2012-10-17 2018-01-29 Univ Okayama Compound, tautomer and geometric isomer thereof, compound, tautomer or salt of geometric isomer, process for preparing the compound, tautomer, isomer or salt, antimicrobial agent and anti-infectious drug
WO2014086102A1 (zh) * 2012-12-06 2014-06-12 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
CN105461609B (zh) * 2015-12-25 2019-08-23 杭州新博思生物医药有限公司 一种尼达尼布的制备方法
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1115704T1 (en) * 1998-09-25 2003-12-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6765012B2 (en) * 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US7005444B2 (en) * 2001-09-27 2006-02-28 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors

Also Published As

Publication number Publication date
JP2005533841A (ja) 2005-11-10
EP1523473B1 (de) 2013-02-27
AU2003254557B2 (en) 2010-07-22
BR0312799A (pt) 2005-05-03
AU2010202845A1 (en) 2010-07-22
WO2004009547A1 (de) 2004-01-29
DK1523473T3 (da) 2013-06-03
MY138141A (en) 2009-04-30
CN1668589A (zh) 2005-09-14
PE20040701A1 (es) 2004-11-30
ECSP055567A (es) 2005-04-18
MXPA04012937A (es) 2005-05-16
CN1318403C (zh) 2007-05-30
KR20120003025A (ko) 2012-01-09
TWI343375B (en) 2011-06-11
AU2003254557A1 (en) 2004-02-09
ES2409062T3 (es) 2013-06-24
KR20050052456A (ko) 2005-06-02
CA2493436A1 (en) 2004-01-29
NO20050937L (no) 2005-02-21
CA2493436C (en) 2011-11-08
EA008623B1 (ru) 2007-06-29
JP4401291B2 (ja) 2010-01-20
AR041188A1 (es) 2005-05-04
TW200413314A (en) 2004-08-01
UY27903A1 (es) 2004-02-27
SA03240430B1 (ar) 2008-03-23
EP1523473A1 (de) 2005-04-20
HK1081554A1 (en) 2006-05-19
PL397821A1 (pl) 2012-03-12
EA200500148A1 (ru) 2005-08-25
IL166404A0 (en) 2006-01-15
PL374879A1 (en) 2005-11-14
HRP20050069A2 (en) 2005-12-31

Similar Documents

Publication Publication Date Title
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
SE0202463D0 (sv) Novel compounds
RS115004A (en) Novel thiophenylglycoside derivatives,methods for production thereof, medicaments comprising said compounds and use thereof
MY122357A (en) Indolinones having kinase inhibitory activity
GEP20074213B (en) Novel inhibitors of kinases
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
TNSN04199A1 (en) Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
MY127956A (en) Substituted indolines which inhibit receptor tyrosine kinases
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
TW200621715A (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
TNSN05194A1 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
WO2004026829A3 (de) Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
YU73900A (sh) Supstituisani indolinoni, njihovo pripremanje i njihova primena kao lekova
AU3864500A (en) Substituted aza-oxindole derivatives
RS20050047A (en) Indoline derivatives substituted in position 6,production and use thereof as medicaments
HK1051858A1 (en) Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof.
WO2001027080A3 (de) In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren
WO2004043956A8 (fr) Composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL165558A0 (en) N-benzoylureidocinnamate derivatives method for production and use thereof
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
TNSN07006A1 (en) Novel heterocyclic compounds
NZ545580A (en) Aminoquinoline derivatives and their use as adenosine A3 ligands